Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates

被引:10
作者
Duan, CY
Poticha, D
Stoeckli, TC
Petropoulos, CJ
Whitcomb, JM
McHenry, CS
Kuritzkes, DR
机构
[1] Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA
[3] ViroLogic, S San Francisco, CA USA
关键词
D O I
10.1086/323995
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cross-resistance between zidovudine, stavudine, and lamivudine was studied, using purified recombinant reverse transcriptase from a zidovudine-susceptible and -resistant pair of clinical isolates of human immunodeficiency virus type 1. The zidovudine-resistant isolate exhibited low-level cross-resistance to both stavudine and lamivudine in drug susceptibility assays. Enzyme from the resistant isolate demonstrated reduced inhibition by zidovudine triphosphate and stavudine triphosphate and, to a lesser extent, lamivudine triphosphate. These findings provide additional evidence at the viral and enzyme level for cross-resistance between zidovudine and stavudine, and they suggest a possible effect of zidovudine resistance on susceptibility to lamivudine.
引用
收藏
页码:1336 / 1340
页数:5
相关论文
共 15 条
[1]   Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT):: Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase [J].
Arion, D ;
Kaushik, N ;
McCormick, S ;
Borkow, G ;
Parniak, MA .
BIOCHEMISTRY, 1998, 37 (45) :15908-15917
[2]   ORDERED APPEARANCE OF ZIDOVUDINE RESISTANCE MUTATIONS DURING TREATMENT OF 18 HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE SUBJECTS [J].
BOUCHER, CAB ;
OSULLIVAN, E ;
MULDER, JW ;
RAMAUTARSING, C ;
KELLAM, P ;
DARBY, G ;
LANGE, JMA ;
GOUDSMIT, J ;
LARDER, BA .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (01) :105-110
[3]  
CALVEZ V, 2000, ANTIVIR THER S, V5, P83
[4]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[5]   Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine [J].
Coakley, EP ;
Gillis, JM ;
Hammer, SM .
AIDS, 2000, 14 (02) :F9-F15
[6]   An analysis of the catalytic cycle of HIV-1 reverse transcriptase: Opportunities for chemotherapeutic intervention based on enzyme inhibition [J].
Furman, PA ;
Painter, GR ;
Anderson, KS .
CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (05) :547-567
[7]   A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V [J].
Hertogs, K ;
Bloor, S ;
De Vroey, V ;
Van den Eynde, C ;
Dehertogh, P ;
Van Cauwenberge, A ;
Stürmer, M ;
Alcorn, T ;
Wegner, S ;
Van Houtte, M ;
Miller, V ;
Larder, BA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :568-573
[8]   STANDARDIZED PERIPHERAL-BLOOD MONONUCLEAR CELL-CULTURE ASSAY FOR DETERMINATION OF DRUG SUSCEPTIBILITIES OF CLINICAL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES [J].
JAPOUR, AJ ;
MAYERS, DL ;
JOHNSON, VA ;
KURITZKES, DR ;
BECKETT, LA ;
ARDUINO, JM ;
LANE, J ;
BLACK, RJ ;
REICHELDERFER, PS ;
DAQUILA, RT ;
CRUMPACKER, CS ;
BALFOUR, H ;
ERICE, A ;
COOMBS, R ;
KATZENSTEIN, D ;
LATHEY, J ;
RICHMAN, D ;
MCINTOSH, K ;
RANGAN, S ;
REICHMAN, R ;
SCOTT, W ;
USSERY, M ;
ABRAMS, L ;
MCCUTCHAN, F ;
BURKE, D ;
GARDNER, L ;
ROBERTS, C ;
CHUNG, R ;
HICKS, C ;
SHELLIE, E ;
FOWLER, A ;
MERRITT, L ;
FUJIMURAJUSTICE, M ;
RUIZ, N ;
WAGNER, K ;
GAIL, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1095-1101
[9]  
JOHNSON V, 2000, ANTIVIR THER S, V5, P42
[10]   HIV WITH REDUCED SENSITIVITY TO ZIDOVUDINE (AZT) ISOLATED DURING PROLONGED THERAPY [J].
LARDER, BA ;
DARBY, G ;
RICHMAN, DD .
SCIENCE, 1989, 243 (4899) :1731-1734